Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Cash from Discontinued Operations: 2021-2024

Historic Cash from Discontinued Operations for Mimedx Group (MDXG) over the last 4 years, with Dec 2024 value amounting to -$930,000.

  • Mimedx Group's Cash from Discontinued Operations fell 99.90% to $1,000 in Q4 2024 from the same period last year, while for Dec 2024 it was -$930,000, marking a year-over-year increase of 88.61%. This contributed to the annual value of -$930,000 for FY2024, which is 88.61% up from last year.
  • Mimedx Group's Cash from Discontinued Operations amounted to -$930,000 in FY2024, which was up 88.61% from -$8.2 million recorded in FY2023.
  • Mimedx Group's 5-year Cash from Discontinued Operations high stood at $7.9 million for FY2021, and its period low was -$9.9 million during FY2022.
  • Over the past 3 years, Mimedx Group's median Cash from Discontinued Operations value was -$8.2 million (recorded in 2023), while the average stood at -$6.3 million.
  • As far as peak fluctuations go, Mimedx Group's Cash from Discontinued Operations plummeted by 225.71% in 2022, and later soared by 88.61% in 2024.
  • Yearly analysis of 4 years shows Mimedx Group's Cash from Discontinued Operations stood at $7.9 million in 2021, then tumbled by 225.71% to -$9.9 million in 2022, then increased by 17.73% to -$8.2 million in 2023, then surged by 88.61% to -$930,000 in 2024.